The company continues to build evidence for the added sensitivity offered by its urine- and blood-based liquid biopsy approach in an effort to engage clinicians.
A new study suggests that EGFR and MAPK protein abundance is the same across cell lines, while the adaptor proteins vary in number.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.
Genentech's Alecensa and AstraZeneca's Tegrisso are the latest precision lung cancer drugs, and Xalkori might soon be an option for a new molecular subpopulation.
Researchers from a SU2C-sponsored study compared tissue biopsy and liquid biopsy for detecting the T790M mutation of the EGFR gene in a cohort of NSCLC patients.
The preliminary results showed that 76 percent of study subjects under 40 had druggable mutations.
In developing the recommendations, the expert panel attempted to keep up with the fast-moving advances in oncology.
Roche's Cobas EGFR v2 mutation test will be able to identify advanced NSCLC patients with EGFR mutations who are likely to benefit from the next-generation treatment.
Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.
The investment bank said that expected launches within the next two years for quantitative assays would bring Trovagene into larger and more profitable markets.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.